Evidence map›Paper›PMID 33005728›Full record

ArticleMolecular therapy oncolytics2020

Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity.

Toshiyasu Sakai, Seitaro Terakura, Kotaro Miyao, Shingo Okuno, Yoshitaka Adachi, Koji Umemura, Jakrawadee Julamanee, Keisuke Watanabe, Hiroshi Hamana, Hiroyuki Kishi and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Toshiyasu SakaiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kotaro MiyaoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shingo OkunoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshitaka AdachiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Koji UmemuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jakrawadee JulamaneeDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Keisuke WatanabeDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroshi HamanaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Judith LeitnerDivision for Immune Receptors and T Cell Activation, Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Peter SteinbergerDivision for Immune Receptors and T Cell Activation, Institute of Immunology, Medical University of Vienna, Vienna, Austria.
Tetsuya NishidaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Makoto MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPMedical University of Vienna · ATUniversity of Toyama · JPPrince of Songkla University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An artificial T cell adaptor molecule (ATAM) was generated to improve persistence of T cell receptor (TCR) gene-transduced T (TCR-T) cells compared to such persistence in a preceding study. ATAMs are gene-modified CD3ζ with the intracellular domain of 4-1BB inserted in the middle of CD3ζ. NY-ESO-1 TCR-T cells transduced with an ATAM with two separated virus vectors demonstrated superior proliferation upon antigen stimulation. To further develop clinically applicable ATAM-transduced TCR-T cells, we attempted to make a single virus vector to transduce the TCR and ATAM simultaneously. Because we failed to observe improved proliferation capacity upon stimulation after one virus vector (1vv) transduction, we compared TCR-T cells transduced with 1vv and two virus vector (2vv) methods to elucidate the reason. In Jurkat reporter cells, an ATAM transduced by the 2vv method demonstrated a higher intensity than by the 1vv method, and the ATAM intensity was associated with increased nuclear factor κB (NF-κB) signals upon stimulation. In ATAM-transduced primary T cells, a transduced ATAM by the 2vv method showed higher intensity and better proliferation. ATAM-transduced TCR-T cells demonstrated improved proliferation only when the ATAM was transduced at a higher intensity. To create a simpler transduction method, we need to develop a strategy to make a higher ATAM expression to prove the efficacy of ATAM transduction in TCR-T therapy.

Indexed as

adaptor molecule gene-insertion intensityartificial adaptor moleculeCD3ζ gene modificationgene-modified T cell therapyT cell receptor gene insertion

Identifiers

PMID33005728
PMCPMC7509457
OpenAlexW3081572768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.